170 related articles for article (PubMed ID: 36469217)
1. New insight into immune checkpoint inhibitors in the treatment of advanced renal cell carcinoma.
Wang H; Zhu Z; Zhang Y; Jiang T; Zhang M; Wang Z; Zhang Y; Zhao A; Su B
Sci China Life Sci; 2023 Apr; 66(4):875-878. PubMed ID: 36469217
[No Abstract] [Full Text] [Related]
2. Combination of cabozantinib and immune checkpoint inhibitors in advanced renal cell carcinoma: update from the European Society for Medical Oncology 2020.
Sarkis J; Khalil N; Alkassis M
Future Oncol; 2021 Mar; 17(9):991-992. PubMed ID: 33533650
[No Abstract] [Full Text] [Related]
3. What advances have been made in immune-therapy for renal cell carcinoma?
Verzoni E; Grassi P; Ratta R
Future Oncol; 2017 Apr; 13(8):665-668. PubMed ID: 28183189
[No Abstract] [Full Text] [Related]
4. Relationship between sex and immune checkpoint inhibitors in urothelial carcinoma and renal cell carcinoma.
Song Y; Peng Y; Qin C
World J Urol; 2023 Aug; 41(8):2301-2302. PubMed ID: 37410104
[No Abstract] [Full Text] [Related]
5. Immunotherapy for metastatic renal cell carcinoma: A brief history, current trends, and future directions.
Rambhia A; Patel RD; Okhawere KE; Korn TG; Badani KK
Urol Oncol; 2021 Oct; 39(10):664-677. PubMed ID: 34312081
[TBL] [Abstract][Full Text] [Related]
6. Immune checkpoint inhibitor combination therapy leads to more nephrotoxicity in advanced renal cell carcinoma patients.
Song Y; Han S; Xu T
World J Urol; 2023 Jul; 41(7):1991-1992. PubMed ID: 37286737
[No Abstract] [Full Text] [Related]
7. Significance of tumor microenvironment in acquiring resistance to vascular endothelial growth factor-tyrosine kinase inhibitor and recent advance of systemic treatment of clear cell renal cell carcinoma.
Mikami S; Mizuno R; Kosaka T; Tanaka N; Kuroda N; Nagashima Y; Okada Y; Oya M
Pathol Int; 2020 Oct; 70(10):712-723. PubMed ID: 32652869
[TBL] [Abstract][Full Text] [Related]
8. Current State of Systemic Therapies for Advanced Renal Cell Carcinoma.
Gulati S; Vaishampayan U
Curr Oncol Rep; 2020 Feb; 22(3):26. PubMed ID: 32048058
[TBL] [Abstract][Full Text] [Related]
9. Patients with sarcomatoid renal cell carcinoma - re-defining the first-line of treatment: A meta-analysis of randomised clinical trials with immune checkpoint inhibitors.
Iacovelli R; Ciccarese C; Bria E; Bracarda S; Porta C; Procopio G; Tortora G
Eur J Cancer; 2020 Sep; 136():195-203. PubMed ID: 32712550
[TBL] [Abstract][Full Text] [Related]
10. Pembrolizumab: first adjuvant immunotherapy in renal cell carcinoma?
Saleh K; Kordahi M; Felefly T; Kourie HR; Khalife N
Future Oncol; 2022 Feb; 18(5):519-522. PubMed ID: 35067079
[No Abstract] [Full Text] [Related]
11. Magnetic resonance imaging criteria of immune checkpoint inhibitor-induced hypophysitis.
Nada A; Bhat R; Cousins J
Curr Probl Cancer; 2021 Feb; 45(1):100644. PubMed ID: 32888700
[TBL] [Abstract][Full Text] [Related]
12. Immune checkpoint inhibitors in advanced renal cell carcinoma: experience to date and future directions.
Atkins MB; Clark JI; Quinn DI
Ann Oncol; 2017 Jul; 28(7):1484-1494. PubMed ID: 28383639
[TBL] [Abstract][Full Text] [Related]
13. Impact of renal cell carcinoma molecular subtypes on immunotherapy and targeted therapy outcomes.
Saliby RM; Labaki C; Jammihal TR; Xie W; Sun M; Shah V; Saad E; Kane MH; Kashima S; Sadak K; El Zarif T; Poduval D; Motzer RJ; Powles T; Rini BI; Albiges L; Pal SK; McGregor BA; McKay RR; Signoretti S; Van Allen EM; Shukla SA; Choueiri TK; Braun DA
Cancer Cell; 2024 May; 42(5):732-735. PubMed ID: 38579722
[TBL] [Abstract][Full Text] [Related]
14. Integrated analysis of immune-related gene subtype and immune index for immunotherapy in clear cell renal cell carcinoma.
Bai D; Chen S; Feng H; Yin A; Lu J; Ma Y; Sugiyama H
Pathol Res Pract; 2021 Sep; 225():153557. PubMed ID: 34329838
[TBL] [Abstract][Full Text] [Related]
15. Roles of the Dynamic Tumor Immune Microenvironment in the Individualized Treatment of Advanced Clear Cell Renal Cell Carcinoma.
Lin E; Liu X; Liu Y; Zhang Z; Xie L; Tian K; Liu J; Yu Y
Front Immunol; 2021; 12():653358. PubMed ID: 33746989
[TBL] [Abstract][Full Text] [Related]
16. Emerging therapeutic approaches in renal cell carcinoma.
Parekh H; Rini BI
Expert Rev Anticancer Ther; 2015; 15(11):1305-14. PubMed ID: 26376584
[TBL] [Abstract][Full Text] [Related]
17. Immune checkpoint blockade in renal cell carcinoma.
Rappold PM; Silagy AW; Kotecha RR; Hakimi AA
J Surg Oncol; 2021 Mar; 123(3):739-750. PubMed ID: 33595892
[TBL] [Abstract][Full Text] [Related]
18. Combination therapy with immune checkpoint inhibitors in advanced renal cell carcinoma: A meta-analysis of randomized controlled trials.
Mo DC; Huang JF; Luo PH; Huang SX; Wang HL
Clin Immunol; 2021 Nov; 232():108876. PubMed ID: 34740840
[TBL] [Abstract][Full Text] [Related]
19. Are immune checkpoint inhibitors a valid option for papillary renal cell carcinoma? A multicentre retrospective study.
de Vries-Brilland M; Gross-Goupil M; Seegers V; Boughalem E; Beuselinck B; Thibault C; Chevreau C; Ladoire S; Barthélémy P; Negrier S; Borchiellini D; Huillard O; Geoffrois L; Gravis G; Saldana C; Thiery-Vuillemin A; Escudier B; Ravaud A; Albiges L
Eur J Cancer; 2020 Sep; 136():76-83. PubMed ID: 32653774
[TBL] [Abstract][Full Text] [Related]
20. The 'nivolution' in renal cell carcinoma: behind the scenes of clinical trials.
Buti S; Bersanelli M
Future Oncol; 2016 Sep; 12(18):2061-3. PubMed ID: 27168416
[No Abstract] [Full Text] [Related]
[Next] [New Search]